The Sema4 Solid Tumor Panel uses next-generation sequencing (NGS) technology to test for actionable somatic mutations in solid tumors.
| Highly accurate | >99% sensitivity and specificity* |
| Comprehensive | >99% of mutations associated with FDA-approved therapies, standard-of-care treatments, and investigational therapies in clinical trials† |
| Actionable | Delivers insights to guide targeted therapy or clinical trial selection |
| Advanced | Powered by the Oncomine platform, a next-generation sequencing solution used by leading global research institutions and clinical trials, including the NCI-MATCH trial |
*Compared against a series of cases with known or previously-tested mutations by other NGS methods.
† Based on an analysis of actionable alterations from OncoKB. For additional information, please see Chakrevarty D, Gao K, Phillips S, et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology. 2017.
